PDS Biotechnology Corporation

Greetings. Welcome to the PDS Biotech's third quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. At this time, we'll turn the conference over to Tom Johnson with LifeSite Advisors. Tom, you may now begin.

Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's third quarter 2025 results and clinical programs update call. I'm joined on the call today by the following members of the company's management team, Dr. Frank Beto-Addo, Chief Executive Officer, Dr. Kirk Shepherd, Chief Medical Officer, and Lars Bozgaard, Chief Financial Officer. Dr. Beto-Addo will begin with an overview of the company's recent progress and its clinical development program. Mr. Boesgaard will review the financial results for the quarter ended September 30, 2025, and Dr. Shepard will then join the call to help address questions from covering analysts. As a reminder, during this call, we will make forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any statements should be considered in conjunction with the cautionary statements in our press release and risk factors discussed in our filings with the SEC. including our quarterly reports on Form 10-Q and our annual report on Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

Now I'd like to turn the call over to Dr. Beto Adu. Frank?